Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 5 mg - finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: -improve symptoms -reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride is contraindicated in the following: hypersensitivity to any component of this medication. pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to dht, finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. (see also warnings, exposure of women — risk to male fetus and precautions, information for patients and pregnancy.) in female rats, low doses of finasterid

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 100 mg - major depressive disorder -sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. the efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical trials under clinical pharmacology). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.  the antidepressant action of sertraline hyd

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate 5 mg - hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. this product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. controlled substance – hydrocodone bitartrate and acetaminophen tablets are classified as a schedule iii controlled substance. abuse and dependence – psychic dependence, physical dependence, and tolerance may develop upon repeated administration of narcotics; therefore, this product should be prescribed and administered with caution. however, psychic dependence is unlikely to develop when hydrocodone bitartrate and acetaminophen tablets are used for a short time for the treatment of pain. physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant prop

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of pati

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 600 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - hydrocodone bitartrate 7.5 mg - hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. hydrocodone bitartrate and ibuprofen are not indicated for the treatment of such conditions as ostearthritis or rheumatoid arthritis. hydrocodone bitartrate and ibuprofen tablets should not be administered to patients who previously have exhibited hypersensitivity to hydrocodone or ibuprofen. hydrocodone bitartrate and ibuprofen should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or the nsaids. severe, rarely fatal, anaphylactoid-like reactions to nsaids have been reported in such patients (see warnings-anaphylactoid reactions, and precautions-pre-existing asthma). patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. controlled substance : hydrocodone bitartrate and ibuprofen tablets are a schedule iii controlled substance. abuse : psychic dependence, physical depen

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson packaging services a business unit of mckesson corporation - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg